drugset
drugset / Trial / NCT04728347

Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021

NCT04728347 ↗

Phase 2 Terminated 65 enrolled Arcturus Therapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label study enrolling healthy adults that participated in Study ARCT-021-01 (the Parent Study). Participants will receive either a single injection of ARCT-021 or no injection and be followed for up to 365 days.

Timeline

Start
2021-01-04
Primary completion
2021-12-28
Completion
2021-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject ARCT-021 Messenger RNA (mRNA) — —

Indications

COVID-19